WASHINGTON (dpa-AFX) - Onyx Pharmaceuticals, Inc. (ONXX) announced that the U.S. Food and Drug Administration's, or FDA, Oncologic Drugs Advisory Committee, or ODAC, will review the company's new drug application, or NDA, for carfilzomib for the treatment of patients with relapsed and refractory multiple myeloma who have received at least two prior therapies.
ODAC will review carfilzomib at its meeting on June 20, 2012. The Prescription Drug User Fee Act date for completion of review by the FDA is July 27, 2012.
Ted Love, executive vice president, Research and Development and Technical Operations at Onyx Pharmaceuticals, stated, 'Multiple myeloma is a deadly disease for which there are no cures, and we are committed to bringing carfilzomib to patients as quickly as possible. Our team looks forward to discussing the potential efficacy benefit and safety profile of carfilzomib with the advisory committee and will continue to work closely with the FDA during its review.'
Copyright RTT News/dpa-AFX
